News

Researchers at Centro Universitário Augusto Motta and Hospital Federal de Bonsucesso in Rio de Janeiro, Brazil recently discovered that muscle strength in the lower limbs of patients with systemic sclerosis influences the patient’s functional capacity and quality of life. The study is entitled “Lower…

Researchers from the University of Cologne in Germany showed that Systemic sclerosis-overlap Syndrome should be regarded as different separate subset in Systemic sclerosis (SSc) patients. The study entitled “Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis” appeared on…

A recent study published in the journal PLOS One reports the results of a comprehensive clinical assessment review in patients with Systemic sclerosis and lung cancer. Systemic sclerosis (SSc) is a connective tissue disorder characterized by immune dysregulation and accumulation of extracellular matrix constituents resulting in…

A case study of a patient with Scleroderma recently published in the journal JAAD Case Reports reports the clinical outcomes of treatment with HDAC (Histone deacetylase inhibition) with divalproex sodium. Scleroderma is a complex autoimmune connective tissue disease, and although the causes remain unclear, research suggests that transforming growth…

Researchers from the Hunter Holmes McGuire VA Medical Center, Richmond, VA, and the Department of Rheumatic and Immunologic Diseases, Orthopedics and Rheumatology Institute, Cleveland Clinic, OH, have recently released results from a clinical trial that evaluated the use of ambrisentan, a selective endothelin type A receptor antagonist,…

The Assistance Publique – Hôpitaux de Paris is collaborating with Actelion Pharmaceutics on a study testing the efficacy, safety and tolerability of bosentan in patients with scleroderma renal crisis on renal function (ClinicalTrials.gov Identifier: NCT01241383). Systemic sclerosis (SSc) is an auto-immune disorder that causes excessive collagen deposition,…

Yuval Cohen (PhD), Chief Executive of Corbus Pharmaceuticals A new proposed treatment for scleroderma will soon be in Phase 2 clinical trials. Corbus Pharmaceuticals, based in Norwood, Massachusetts, recently received clearance from the FDA for their investigational new drug (IND),…

Cytori Therapeutics, Inc. recently announced an FDA approval that will allow them to expand the number of sites in the United States from 12 to 20 centers where the company’s Scleroderma clinical trials are currently being conducted. The STAR study was approved by the FDA in January 2015 as an 80-patient…

Cytori Therapeutics, Inc. recently announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has given a positive opinion concerning Cytori’s submission for an orphan drug designation for ECCS-50, the company’s experimental Scleroderma therapeutic, which is based on stromal vascular fraction cells, from adipose tissue and derived from Celution® System,…

A recent study published in the journal Arthritis Research & Therapy analyzed different prediction algorithms for the efficient diagnosis of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis. The study is entitled “A comparison of the predictive accuracy of three screening models…